'OBJ has been developing its magnetic transdermal technology for more than 12 years under the direction of founder, inventor and managing director Jeffrey Edwards. Mr Denison said he met Mr Edwards on a flight and asked what he did for a living, and as a type 1 insulin-dependent diabetes patient, Mr Edwards “instantly had my attention”. Mr Edwards said that the problem with using the magnetic micro-array platform for drugs like insulin was not the size of the molecule, but the large volume of drug required to be delivered. Mr Edwards explained that the thin magnetic micro-array strips could be “tuned to specific molecules” to enhance their penetration of the skin using electro-magnetic forces.'
Jase and others who especially have been around a while (and of course everyone else); I can't help but wonder why over the years we have continued to be reminded of this story and Mr Denison's Type 1 Diabetes? Why did Mr Edwards Instantly have Mr Denison's attention? Is it possible that one of OBJ's collaborating partners are investigating one of OBJ's Platforms for the delivery of Insulin as well? Mr Edwards has already admitted that the size of the Insulin molecule was not the problem but rather the volume of drug required. Could one of our powered platforms take care of the 'volume' issue by perhaps a hybridised version with a microneedle similar to the Vaccine program that mysteriously went into stealth mode? And who would most likely be investigating a candidate for Insulin delivery over the last 10 or so years?
GSK/Novartis (Avandamet & Metformin):
Background
GlaxoSmithKline is the world's second largest pharmaceutical and consumer healthcare company with products ranging from vaccines and oncology products through to over‐ the‐counter medicines and nutritional products. OBJ first collaborated with GSK in 2006 in an advanced delivery program employing the Company’s Dermaportation technology.This program was further expanded to involve both the Company’s Dermaportation and ETP technologies. This relationship was announced to shareholders in May 2007 following approval of that release by GSK. A further confidential collaboration with GSK was undertaken in 2008 in an undisclosed consumer healthcare field and the current announcement continues the work in that same commercial field. The results, application field and drug used in the current program are, by agreement, to remain confidential.
Imo, a Pharmaceutical Application in any form of one of OBJ's Technology Platforms would most definately add a new dimension to the recent buying. We are already talking 10 years maturity on the GSK trials that have remained confidential up until this point in time .
OBJ Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
.
(20min delay)